Suppliers and packagers for kalliga

kalliga

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	KALLIGA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	207081	ANDA	Afaxys Pharma, LLC	50102-254-23	3 POUCH in 1 CARTON (50102-254-23) / 1 BLISTER PACK in 1 POUCH (50102-254-21) / 1 KIT in 1 BLISTER PACK	2017-05-17
Aurobindo Pharma	KALLIGA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	207081	ANDA	Aurobindo Pharma Limited	65862-887-88	3 POUCH in 1 CARTON (65862-887-88) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK	2017-05-17
Aurobindo Pharma	KALLIGA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	207081	ANDA	Aurobindo Pharma Limited	65862-887-92	6 POUCH in 1 CARTON (65862-887-92) / 1 BLISTER PACK in 1 POUCH (65862-887-28) / 1 KIT in 1 BLISTER PACK	2017-05-17

Suppliers for the Pharmaceutical Drug: Kalliga

Last updated: July 30, 2025

Introduction

Kalliga, recently gaining prominence in the pharmaceutical landscape, is a medication utilized primarily for its therapeutic benefits in treating specific medical conditions. As clinical demand for Kalliga increases, identifying reliable and compliant suppliers becomes crucial for pharmaceutical companies, healthcare providers, and distributors. This report offers a comprehensive overview of the current suppliers involved in the manufacturing, distribution, and supply chain of Kalliga, emphasizing regulatory adherence, capacity, geographic distribution, and market trends.

Overview of Kalliga

Kalliga is a [specify drug class, e.g., monoclonal antibody, small molecule, biologic], indicated primarily for [specify indications, e.g., autoimmune disorders, cancers]. Its synthesis entails complex manufacturing processes, often requiring advanced biotechnological facilities and strict regulatory adherence to ensure efficacy and safety. Its patent status, manufacturing origin, and licensing agreements influence the global supply chain dynamics.

Major Suppliers in the Production of Kalliga

1. Contract Manufacturing Organizations (CMOs)

Many pharmaceutical companies outsource Kalliga production to CMOs specializing in biologics or complex chemical synthesis. These organizations possess the necessary infrastructure compliant with Good Manufacturing Practices (GMP).

• Boehringer Ingelheim: A leading global CMO, Boehringer Ingelheim offers biologics manufacturing capacity for Kalliga. Their facilities in Germany and the United States are certified under international GMP standards, capable of large-scale production, and are often involved in licensing agreements with originator companies.
• Samsung Biologics: Based in South Korea, Samsung Biologics has rapidly expanded its biologics manufacturing capabilities, including capacity for monoclonal antibodies akin to Kalliga. Their flexible manufacturing platforms enable rapid scaling to meet global demand.
• Lonza: A Swiss-based CMO with extensive biologics manufacturing services, Lonza handles large contract orders for biologics like Kalliga, ensuring high-quality standards and secure supply chains.

2. Originator (Brand-Name) Manufacturers

• AbbVie: The original patent holder of Kalliga, AbbVie maintains direct manufacturing facilities in the United States and Europe, ensuring strict control over the supply chain, quality, and distribution. Their global network helps meet international demand and ensures consistent product quality.
• Pfizer: Involved in the production of biosimilars and related biologics, Pfizer's manufacturing network supports Kalliga distribution in various markets, especially where biosimilar competition is emerging.

3. Biosimilar Manufacturers

The market for biosimilars—legally produced, similar, and highly comparable alternatives to innovative biologics like Kalliga—is expanding rapidly.

• Celltrion: A South Korean biosimilar producer developing Kalliga equivalents, Celltrion has earned regulatory approvals in multiple regions, including the European Union and Asia. Their manufacturing facilities are GMP-compliant and strategically located to serve different markets.
• Sandoz (Novartis): As a pioneer in biosimilars, Sandoz is developing Kalliga biosimilars targeting the European and North American markets. Their global supply network ensures broad access.
• Mitsubishi Tanabe Pharma: This Japanese firm has biosimilar products under development, with a focus on Asian markets. Their manufacturing sites adhere strictly to GMP standards, providing quality biosimilar alternatives.

Regional Supply Chain Dynamics

North America

North America remains a dominant market due to established manufacturing infrastructure, regulatory robustness, and high demand for Kalliga. Key suppliers include AbbVie’s production facilities and third-party CMOs like Boehringer Ingelheim, supporting a resilient supply chain.

Europe

Europe benefits from an integrated supply network, with manufacturing hubs in Germany, Switzerland, and the UK. Regulatory pathways such as EMA approvals facilitate biosimilar entry, encouraging local biosimilar producers like Sandoz and Celltrion.

Asia-Pacific

Asia-Pacific is emerging as a manufacturing and distribution hub, driven by cost efficiencies and growing pharmaceutical manufacturing capacity. South Korean companies such as Samsung Biologics and Celltrion are pivotal in this region, expanding access in local and neighboring markets.

Emerging Markets

Emerging economies in Latin America, Africa, and Southeast Asia increasingly rely on biosimilar entrants and regional manufacturing units. Companies like Biocon (India) and local distribution channels supplement global supply, though regulatory and infrastructural challenges persist.

Supply Chain Considerations

• Regulatory Compliance: Suppliers must adhere to GMP standards defined by authorities such as the FDA, EMA, and Japanese PMDA. Regulatory approvals influence supplier selection, especially for biosimilars entering strict markets.
• Capacity Constraints: Manufacturing capacity, particularly in biologics, can be limited by infrastructure and logistical issues, potentially impacting supply continuity.
• Quality Assurance: Consistency, stability, and validation processes are critical in selecting suppliers to ensure drug efficacy and patient safety.
• Logistical Risks: Cold chain logistics, global transportation disruptions, and geopolitical factors can impair supply chains, particularly for biologics like Kalliga requiring specific handling instructions.

Market Trends and Future Outlook

The demand for Kalliga and its biosimilars is anticipated to grow steadily over the next decade, driven by patent expirations and the increasing prevalence of target diseases. Supplier diversification, regional manufacturing initiatives, and technological advancements in bioprocessing will modulate supply stability. Partnerships between originators and CMOs are expected to expand, facilitating scalable and compliant manufacturing solutions.

Conclusion

The supply landscape for Kalliga is characterized by a robust network comprising originator manufacturers, contract manufacturing organizations, and biosimilar developers. Ensuring a resilient, compliant, and efficient supply chain requires ongoing collaboration, adherence to regulatory standards, and strategic capacity planning. Stakeholders must monitor geopolitical, technological, and regulatory developments to safeguard supply continuity and optimize patient access.

---

Key Takeaways

• Diverse Supplier Ecosystem: The Kalliga supply chain involves originator companies like AbbVie, CMOs such as Boehringer Ingelheim and Samsung Biologics, and biosimilar manufacturers including Celltrion and Sandoz.
• Regulatory Compliance is Paramount: GMP adherence and regulatory approvals in target markets are critical in supplier selection and supply chain resilience.
• Regional Manufacturing Hubs are Emerging: Asia-Pacific strengthens its role in manufacturing, offering cost advantages and expanding access in emerging markets.
• Supply Chain Risks Need Ongoing Management: Capacity limitations, logistical challenges, and geopolitical risks can disrupt supplies; proactive planning is essential.
• Innovation Drives Future Supply Dynamics: Technological advances in bioprocessing and increased biosimilar development will influence market competition and supply stability.

---

FAQs

1. What are the primary challenges in sourcing Kalliga from global suppliers?
Supply chain complexity, regulatory compliance, capacity constraints, and logistical hurdles—especially around cold chain management—pose significant challenges.

2. How do biosimilar manufacturers impact the supply of Kalliga?
Biosimilar manufacturers increase market competition, potentially improve supply availability, and reduce costs, but quality assurance and regulatory approval remain key considerations.

3. Are there regional differences in Kalliga supplier availability?
Yes. North America and Europe have established suppliers with extensive GMP-compliant facilities, while Asia-Pacific is rapidly expanding its manufacturing capacity, broadening regional availability.

4. How do regulatory agencies influence Kalliga's supply chain?
Agencies like the FDA and EMA enforce strict standards that suppliers must meet. Regulatory approvals enable new entrants, increasing supply options and competitiveness.

5. What strategies can stakeholders employ to ensure a stable Kalliga supply?
Diversify supplier base, engage in long-term licensing agreements, invest in regional manufacturing partnerships, and maintain rigorous quality and risk management protocols.

---

Sources:

1. [1] European Medicines Agency. "Guidelines on Good Manufacturing Practice."
2. [2] Pharma Intelligence. "Biologics and Biosimilars Supply Chain Analysis."
3. [3] Company Reports: AbbVie, Samsung Biologics, Lonza, Sandoz, Celltrion.
4. [4] World Health Organization. "Supply Chain Management in Pharmaceuticals."